Future Research Goals in Immunotherapy.

Publication Title

Surgical oncology clinics of North America

Authors

Tyler W Hulett, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, 2N56 North Pavilion, 4805 NE Glisan St., Portland, OR, 97213, USA.Follow
Bernard A Fox, Chiles Research Institute Providence Portland Medical CenterFollow
David J Messenheimer
Sebastian Marwitz, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, ORFollow
Tarsem Moudgil, Earle A. Chiles Research Institute, Providence Cancer InstituteFollow
Michael E Afentoulis, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, 2N56 North Pavilion, 4805 NE Glisan St., Portland, OR, 97213, USA.Follow
Keith W Wegman, Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USAFollow
Carmen Ballesteros-Merino, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.Follow
Shawn M. Jensen, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, Portland, OregonFollow

Document Type

Article

Publication Date

7-1-2019

Keywords

Biomarkers; Cancer vaccines; Combination immunotherapy; Immunoprofiling; Seromics; T-cell agonists

Abstract

In our opinion the most urgent needs to improve patient outcomes are: 1) a deeper ability to measure cancer immunobiology, and 2) increased availability of agents that, coupled with predictive biomarkers, will be used to tailor anti-cancer immunity. Tailoring effective immunotherapy will entail combinations of immunotherapeutics that augment priming of anti-cancer immunity, boost expansion of effector and memory cells of the T, B and NK lineage, amplify innate immunity and relieve checkpoint inhibition. Alternatives to inducing adaptive immunity to cancer include synthetic immunology that incorporate bi-specifics that target T cells to cancer or adoptive immunotherapy with gene-modified immune cells.

Specialty/Research Institute

Earle A. Chiles Research Institute

Specialty/Research Institute

Oncology